Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Siglec-15 antibody–GM-CSF chimera suppresses tumor progression via reprogramming tumor-associated macrophages

1 Apr 2025

Abstract excerpt

BACKGROUND: T cell exhaustion and limiting immunotherapy efficacy. Both blockade of immune checkpoint molecule Siglec-15 and promotion of granulocyte-macrophage colony-stimulating factor (GM-CSF) have been respectively employed in anticancer immunotherapy. METHODS: Murine CT26 or MC38 cancer cells were used to establish subcutaneous tumor models in BALB/c or C57BL/6 mice. Tumors were treated with anti-Siglec-15...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Immune cells in cancer
Share to Immunotherapy and Immune Responses

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40216442
DOI: 10.1136/jitc-2024-010580

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Siglec-15 antibody–GM-CSF chimera suppresses tumor progression via reprogramming tumor-associated macrophagesPMID 40216442Read ↗

Single-Dose Anti–PD-L1/IL-15 Fusion Protein KD033 Generates Synergistic Antitumor Immunity with Robust Tumor-Immune Gene Signatures and Memory ResponsesSemantic proximity Read ↗

Siglec-15 is a glyco-immune checkpoint in prostate cancer regulating immune evasion and metastasisSemantic proximity Read ↗

Therapy-induced senescent-like cancer cells drive macrophage-mediated immunosuppression in cholangiocarcinomaSemantic proximity Read ↗

Siglec-15 as an Emerging Target for Next-generation Cancer ImmunotherapySemantic proximity Read ↗

IL-15 synergizes with CD40 agonist antibodies to induce durable immunity against bladder cancerSemantic proximity Read ↗

Heterodimeric IL15 Treatment Enhances Tumor Infiltration, Persistence, and Effector Functions of Adoptively Transferred Tumor-specific T Cells in the Absence of LymphodepletionSemantic proximity Read ↗

Therapeutic potential of interleukin‑15 in cancer (Review)Semantic proximity Read ↗

Next-generation anti-PD-L1/IL-15 immunocytokine elicits superior antitumor immunity in cold tumors with minimal toxicitySemantic proximity Read ↗

Optimized gene engineering of murine CAR-T cells reveals the beneficial effects of IL-15 coexpressionSemantic proximity Read ↗

Eradication of Neuroblastoma by T Cells Redirected with an Optimized GD2-Specific Chimeric Antigen Receptor and Interleukin-15Semantic proximity Read ↗

Interleukin-15-armored GPC3-CAR T cells for patients with solid cancersSemantic proximity Read ↗

OPS-γδ: allogeneic opsonin-secreting γδT cell immunotherapy for solid tumours mediates direct and bystander immunitySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.